BB Biotechs building blocks

BB Biotech shares were listed on the Swiss stock exchange on December 27, 1993. Initial market capitalization was around CHF 340 million. Currently, BB Biotech has more than CHF 3.5 billion, making it one of the largest biotech investors in the world. Including the dividend, the share has had a total return of more than 2000% in CHF since its stock market debut. 

The basis for this performance is BB Biotech's portfolio. The experienced and highly specialized investment team constructs a concentrated and balanced portfolio of 20- 35 investments from an investment universe of more than 1000 biotech companies. In addition to successful large caps, it focuses on innovative mid and small caps, undiscovered biotech pearls with high growth potential.  The investment team not only focuses on companies from established areas such as oncology, rare diseases and neurological indications, but also focuses at an early stage on future technologies that potentially offer novel treatment methods with a promising therapeutic profile and economic benefit. These include technologies such as RNA platforms or cell- or gene-based approaches.

Learn more about our success factors pioneering spirit, growth and know-how.

Exploring opportunities

read more

Exploring opportunities

Attractive biotech companies

read more

Attractive biotech companies

Experienced management team

read more

Experienced management team

BB Biotech app - invest and grow in real-time

The BB Biotech App gives you access to BB Biotech's real-time share price on all stock exchanges, the current portfolio and news on the biotech sector. The app helps you to analyze the current portfolio of BB Biotech, to determine the individual price threshold for buying and selling or simply checking the current Net Asset Value (NAV). With this app, you can do all this with just a few clicks and at any time, wherever you are.

 

 

Head BB Biotech Investment Team im Interview mit finews.ch

Latest News

Media releases / 19.07.2019

Consolidation leaves a mark on results